AGÕæÈ˹ٷ½

STOCK TITAN

Natera Inc SEC Filings

NTRA NASDAQ

Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Parsing Natera’s genomic jargon isn’t easy. Each 10-K details everything from cfDNA assay accuracy to payer reimbursement disputes, while 8-K updates often cover fast-moving clinical-trial milestones. If you’ve ever wondered how to locate test-volume data, or needed Natera insider trading Form 4 transactions before the market reacts, you know the challenge.

Stock Titan solves it. Our AI reads every Natera quarterly earnings report 10-Q filing, highlights revenue per test, and translates accounting footnotes into plain language. AGÕæÈ˹ٷ½-time alerts flag Natera Form 4 insider transactions real-time, so you can track executive stock moves the moment they hit EDGAR. Need the full picture? We link each 10-K, 10-Q, 8-K, proxy DEF 14A, and S-8 in one placeâ€�Natera SEC filings explained simply. Common questions such as “How do I find the latest Natera proxy statement executive compensation?â€� or “Where is the Natera 8-K material events explained?â€� are answered inside every filing card.

Our platform doesn’t stop at document delivery. AI-powered summaries spotlight what matters for a diagnostics company: R&D spend versus cash on hand, progress of the Signatera oncology pipeline, and changes in CMS reimbursement that can swing margins. Use cases include:

  • Compare quarter-over-quarter test volumes without sifting through tables
  • Monitor Natera executive stock transactions Form 4 for buying or selling trends
  • Assess dilution risk by reviewing shelf registrations and ATM offerings
  • Download an Natera annual report 10-K simplified PDF automatically annotated by AI
  • Receive instant alerts when a new Natera earnings report filing analysis is available
  • Get guidance on understanding Natera SEC documents with AI-generated glossaries

Whether you’re a healthcare analyst, portfolio manager, or clinician-investor, Stock Titan turns Natera’s dense disclosures into actionable insight—no genetics PhD required.

Rhea-AI Summary

Natera, Inc. (NTRA) â€� Form 4 filing

CFO Michael Burkes Brophy reported a routine set of transactions tied to RSU vesting and a previously adopted Rule 10b5-1 plan.

  • RSU conversion: On 22 Jul 2025, 1,250 restricted stock units vested and were converted to common shares (Code M).
  • Share sales: The executive sold 2,170 shares across four trades on 22-24 Jul at weighted-average prices of $139.20-$141.28 to cover tax-withholding and liquidity needs.
  • Net change: Beneficial ownership fell by 1,250 shares, leaving Brophy with 70,494 common shares (<â‰�1.8% reduction) and 1,250 unvested RSUs.
  • Plan status: All dispositions were executed under a 10b5-1 plan adopted 14 Jun 2024, limiting discretionary timing.

No other corporate events or material financial information are disclosed in this filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
insider
-
Filing
Rhea-AI Summary

Shimmick Corp. (SHIM) â€� Form 144 filing discloses that insider Mitchell B. Goldsteen plans to sell up to 3,900 common shares through TD Securities on or about 24 Jul 2025. At the most recent market price used in the filing, the sale would raise roughly $8.1 k. The proposed shares represent less than 0.01 % of the company’s 34.36 m shares outstanding.

The notice also lists an extensive series of prior open-market sales by Goldsteen during the past three months. Adding the individual transactions shown, the insider has already disposed of �252 k shares, generating cumulative gross proceeds of several hundred thousand dollars. The new 3,900-share lot suggests continued selling momentum.

No financial performance data, corporate events or explanatory remarks accompany the filing; Form 144 only signals a potential disposition. Investors typically view persistent insider selling—particularly at this scale—as a bearish sentiment indicator, although the absolute percentages remain small relative to total shares outstanding.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.35%
Tags
other
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Filing
Rhea-AI Summary

Millennium Management LLC and affiliates filed a Schedule 13G disclosing a passive stake in AngioDynamics, Inc. (ANGO). As of 16 Jul 2025 the group beneficially owns between 2.12 M and 2.15 M common shares, equal to ~5.2-5.3 % of the outstanding stock. All voting and dispositive power is reported as shared; no sole authority exists.

The filing covers four reporting persons � Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and founder Israel A. Englander. Each entity is organized in Delaware (Englander is a U.S. citizen) and the shares are held through investment vehicles controlled by Millennium. The group certifies the position was acquired solely for investment purposes and not to influence control of the issuer.

Crossing the 5 % ownership threshold on 07/16/25 triggered the disclosure; a joint filing agreement dated 21 Jul 2025 is included. No purchase prices or additional transaction details are provided.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Filing
Rhea-AI Summary

JPMorgan Chase & Co. filed Amendment No. 2 to Schedule 13G on 22 Jul 2025, reporting a passive ownership position in MGIC Investment Corp. (MTG) as of 30 Jun 2025.

The banking group beneficially owns 18,111,064 common shares, equal to 7.6 % of MTG’s outstanding stock. It holds sole voting power over 16,927,029 shares and sole dispositive power over 18,072,928 shares; only 12,463 shares carry shared dispositive power, and none carry shared voting power.

The stake is held “in the ordinary course of business� under Rule 13d-1(b), with JPMorgan classified as a parent holding company (HC). Subsidiaries involved include J.P. Morgan Securities LLC, JPMorgan Chase Bank N.A., and others. The disclosure meets the >5 % threshold but contains no intent to influence control.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

What is the current stock price of Natera (NTRA)?

The current stock price of Natera (NTRA) is $138.9 as of July 25, 2025.

What is the market cap of Natera (NTRA)?

The market cap of Natera (NTRA) is approximately 18.8B.

What core services does Natera Inc offer?

Natera Inc offers a suite of genetic testing services, including non-invasive prenatal testing, carrier screening, oncology diagnostics, and transplant rejection assessments. Each service is supported by advanced bioinformatic algorithms and molecular technologies.

How does Natera ensure accuracy in its testing processes?

Natera leverages proprietary bioinformatic algorithms and rigorous scientific methods to process complex genomic data. This technology-driven approach underpins the accuracy and reliability of its prenatal, oncology, and other genetic tests.

What is non-invasive prenatal testing (NIPT) and how does Natera apply it?

Non-invasive prenatal testing (NIPT) involves screening for genetic abnormalities through a simple maternal blood draw. Natera’s Panorama test applies this technique to provide early genetic insights and reduce risks associated with invasive testing methods.

What role does bioinformatics play in Natera's diagnostic solutions?

Bioinformatics is central to Natera’s approach, converting raw genomic data into clinically actionable insights. The integration of computing with molecular diagnostics allows the company to deliver detailed, accurate results across its testing portfolio.

How does Natera address the needs of oncology patients?

Through its Signatera test, Natera detects circulating tumor DNA to monitor molecular residual disease in cancer patients. This aids in evaluating treatment effectiveness and detecting potential recurrence, thereby supporting informed clinical decisions.

In what ways does Natera contribute to the field of genetic diagnostics?

Natera is at the forefront of advancing genetic diagnostics by integrating cutting-edge molecular science with innovative bioinformatic techniques. This combination ensures highly accurate testing in prenatal, reproductive, and oncology settings.

How is Natera positioned within the competitive landscape of diagnostic companies?

Natera distinguishes itself by focusing on precise, scientifically validated testing and comprehensive genetic counseling services. While facing competition from similar diagnostic firms, its unique blend of technology and expertise sets it apart in specialized clinical applications.
Natera Inc

NASDAQ:NTRA

NTRA Rankings

NTRA Stock Data

18.82B
131.60M
3.45%
93.67%
2.13%
Diagnostics & Research
Services-medical Laboratories
United States
AUSTIN